Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Shareholder Meeting (November 2020)
15 slides from Emvision Medical Devices's shareholder meeting presentation, Nov 26, 2020
Slide 1: AGM Chairman's Address & CEO Presentation
26/11/20 EMvision Medical Devices Ltd ACN 620 388 230 Level 10, 12 Creek Street, Brisbane Qld 4000 02 8667 5337 contact@emvision.com.au For personal use only AGM CHAIRMAN’S ADDRESS & CEO PRESENTATION EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”), is pleased to provide the
Slide 2: Chairman's address conclusion and contacts
To ensure that we are in a strong position to accelerate our product development and clinical validation activities, EMVision completed an oversubscribed capital raising during the year. On behalf of the board I would like to thank all new and existing shareholders who supported the placement. I loo
Slide 3: About Stroke / About EMVision Medical Devices
About Stroke Stroke causes an enormous health and economic burden throughout the world. Stroke is the second leading cause of death and the third leading cause of disability. Imaging is the key to diagnosis and monitoring of acute stroke. The treatments offered require differentiation between ischae
Slide 4: AGM 2020 CEO Presentation
www.emvision.com.au For personal use only AGM - 2020 CEO PRESENTATION
Slide 5: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by EMVision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securiti
Slide 6: Team
TEAM Significant experience developing and commercialising medical devices For personal use only Dr Ron Weinberger John Keep Scott Kirkland Prof Stuart Crozier Robert Tiller Forough Khandan CEO & MD Non-Executive Chairman Executive Director Co-inventor Head of Design Head of Program Management Forme
Slide 7: Transformative Point-of-Care Imaging
TRANSFORMATIVE POINT-OF-CARE IMAGING For personal use only FAST SAFE PORTABLE VIDEO ACCESSIBLE Video available on EMVision website (www.emvision.com.au) ADDRESSING ACCESSABILITY LOW-COST HARDWARE PLATFORM MODALITY 2/3rds of the world does Energy emitted from a scan is Applications across the not hav
Slide 8: 2020 Highlights
2020 HIGHLIGHTS For personal use only VERY ENCOURAGING Promising imaging capabilities, and very encouraging accuracy in CLINICAL TRIAL OUTCOMES stroke type differentiation and localization from the 30 patient dataset INVALUABLE DATASET Dataset to tune and advance algorithms’ ability to detect, local
Slide 9: EMVision's Pilot Clinical Trial
EMVISION’S PILOT CLINICAL TRIAL For personal use only STUDY DESIGN STUDY OBJECTIVE PATIENT COHORT PILOT CLINICAL TRIAL PRIMARY END POINT ACHIEVED 30 STROKE PATIENTS ENROLLED • The single-site study, at the Princess • The primary endpoint was the collection of a • The study enrolled and processed Ale
Slide 10: Fusion with Classifier - Examples
FUSION WITH CLASSIFIER - EXAMPLES Ground Truth Fusion Fusion + Classification Ground Truth Fusion Fusion + Classification For personal use only R L R L R L R L R L R L Haemorrhagic Ischaemic R L R L R L R L R R L L R L R L R L R L R L R L R L R L R L R L R L R L www.emvision.com.au 7 The above examp
Slide 11: Study Outcomes & Upcoming Milestones
STUDY OUTCOMES & UPCOMING MILESTONES For personal use only 93.3% - 96%* 86.7% - 96%* ACCURACY ACCURACY STROKE SUBTYPE LOCALISATION IN OPERATOR AND CLASSIFICATION CORRECT QUADRANT PATIENT FEEDBACK Collect data from stroke patients, Compare EMVision scans with Despite being a prototype, positive both
Slide 12: 1st Generation Device Under Development
1ST GENERATION DEVICE UNDER DEVELOPMENT For personal use only I M P R OV I N G U S E R I N T E R FA C E , U S A B I L I T Y, S O F T W A R E I N T E G R AT I O N A N D H A R D WA R E D E S I G N I N G F O R M A N U FA C T U R E A N D R E G U L AT O R Y S U B M I S S I O N S ACCESSORIES AND ALGORITHM
Slide 13: Clinical & Economic Value of EMVision's 1st Generation Device
CLINICAL & ECONOMIC VALUE OF EMVISION’S 1ST GENERATION DEVICE For personal use only IN-HOSPITAL STUDY OVERVIEW STUDY OBJECTIVES STUDY METHODOLOGY STAKEHOLDERS INTERVIEWED Identify the clinical applications of in-hospital Primary Market Research at two large stroke patient monitoring using EMVision E
Slide 14: Interim Findings: In-Hospital Opportunity
Research & Modelling conducted by; INTERIM FINDINGS IN-HOSPITAL OPPORTUNITY FOR EMVISION POTENTIAL ECONOMIC VALUE TO HOSPITAL* For personal use only GAPS IN CURRENT STROKE MANAGEMENT There is economic value in the early identification of worsening Clinical assessments are done frequently but can be
Slide 15: Australian Stroke Alliance – A Shared Vision
AUSTRALIAN STROKE ALLIANCE – A SHARED VISION For personal use only THE PROBLEM THE SOLUTION 8 million Australians live Tyranny of distance and in rural, remote and inequality of access to indigenous settings with stroke units - 77% urban virtually no access to versus only 3% for rural reperfusion th
EMVision Medical Devices — Shareholder Meeting (November 2020) on 6ix